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B R I E F  R E P O R T
Actinotignum schaalii Infection: 
A Clandestine Cause of Sterile Pyuria?
Lucy E. Horton,1 Sanjay R. Mehta,1 Lejla Aganovic,2 and Joshua Fierer1
1Department of Medicine, VA San Diego Healthcare System and University of California, San 
Diego, School of Medicine, San Diego, California; 2Department of Radiology, VA San Diego 
Healthcare System, San Diego, California
Actinotignum schaalii is an underappreciated cause of urinary 
tract infections (UTIs) in older adults. The diagnosis may be 
missed due to difficulty isolating and identifying the organism. 
Complications can result because the organism is intrinsically 
resistant to 2 commonly used drugs to treat UTI, as illustrated 
by this case.
Keywords. Actinotignum schaalii; chronic prostatitis; 
epididymitis; orchitis; urinary tract infection (UTI).
 
Actinotignum schaalii is increasingly being recognized as a cause 
of urinary tract infections (UTIs) in older adults. A.  schaalii 
(formerly named Actinobaculum schaalii) is a small, Gram-
positive coccoid rod that is part of the normal microbiota. In 
1997, it was reclassified from the genus Actinomyces [1]. It is dif-
ficult to identify in urine with typical microbiology laboratory 
techniques, as it grows slowly and cannot be definitely identi-
fied using standard biochemical assays. Additionally, A. schaalii 
may be mistaken for normal skin flora such as Corynebacterium 
and dismissed as a contaminant. Identification may require the 
use of molecular methods such as 16s rDNA sequencing and/
or Matrix Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry.
A.  schaalii is a facultative anaerobe that grows slowly (4 to 
5 days) on enriched blood agar media in 5% carbon dioxide or 
in an anaerobic atmosphere. It is catalase and oxidase negative 
and does not reduce nitrate to nitrite. It is almost uniformly sus-
ceptible to beta-lactam antibiotics, but almost always resistant 
to TMP-SMX and fluoroquinolones [2].
Most clinical reports involving A.  schaalii describe it as 
a cause of UTIs, typically in the elderly and in those with 
 underlying urologic conditions. It has also been reported to 
cause bacteremia and associated complications including endo-
carditis and osteomyelitis. Interestingly, nearly all reports about 
this uro-pathogen originate from Europe [3–7].
Here we describe a case of a man with chronic prostatitis 
and acute epididymo-orchitis and relapsing epididymitis due to 
A. schaalii.
CASE
A 73-year-old male was referred to our infectious diseases 
clinic for evaluation of recurrent epididymitis with negative 
urine cultures. His medical history was notable for benign pros-
tatic hypertrophy, osteoarthritis, hypertension, depression, and 
post-traumatic stress disorder.
He was first found to have an elevated prostate-specific 
antigen (PSA) 19  years earlier during routine age-recom-
mended screening. At that time, he underwent prostate biopsy, 
which showed only glandular hyperplasia and no malig-
nancy. Over the next 18  years, the PSA remained chronically 
elevated and gradually rose to a baseline of 10 ng/mL, with 2 
documented peak values over 16 ng/mL. During this time, his 
prostate was repeatedly noted to be enlarged on exam, but he 
never had any urinary symptoms or systemic infections. He 
underwent 4 additional prostate biopsies, with histopathology 
on all showing only benign tissue with glandular hyperplasia 
and chronic inflammation. He also had multiple additional cys-
toscopies and magnetic resonance imaging scans demonstrat-
ing prostatic hypertrophy without any evidence of malignancy. 
Approximately 3 years into this course, he was evaluated by a 
urologist for his persistently elevated PSA, and although he was 
asymptomatic, he was treated with levofloxacin for 1 month for 
chronic prostatitis based on his biopsies and elevated PSA, but 
had no clinical improvement..
Two years prior to our encounter, he presented to the emer-
gency department with left testicular swelling without pain or 
any urinary symptoms. Scrotal ultrasound showed left-sided 
epididymo-orchitis. Urinalysis showed pyuria (>100 WBC/
hpf), but routine aerobic culture was negative (urine Gram 
stain was not performed). He was treated with oral ciproflox-
acin for 14 days, and his symptoms resolved. A post-treatment 
urinalysis was normal. He remained symptom-free for almost 
2 years until he again developed swelling of his left testicle with 
mild pain but without dysuria or urinary frequency. At this 
time, his dipstick urinalysis was negative, and after evaluation 
by his primary care doctor, he was treated for epididymitis 
with oral ciprofloxacin for 10  days. His symptoms improved, 
but 2 weeks after treatment was stopped, he developed recur-
rent pyuria and microscopic hematuria. Several weeks after this 
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episode, his PSA increased from his baseline of 12  ng/mL to 
21 ng/mL, but returned to 12 ng/mL 2 months later. He denied 
any prior history of sexually transmitted infections and has not 
been sexually active for several years. He works as a building 
contractor and stated that each episode of epididymitis had 
started shortly after he lifted a heavy object.
During our evaluation in the infectious diseases clinic, he 
was asymptomatic, but a urine culture obtained after prostatic 
massage yielded a heavy growth of bacteria that was misiden-
tified as Gardnerella vaginalis based on Gram stain, colony 
appearance, slow growth, and a positive hippurate test. He was 
not treated for this organism, and when he returned 1 month 
later for his scheduled follow-up, he was having another recur-
rence of left-sided epididymitis with a swollen, erythematous 
testicle and urinary urgency, but without fevers or other symp-
toms of a systemic infection. This episode also began after he 
lifted a heavy object. Urinalysis showed many white blood cells, 
pH 8, and negative nitrites. The Gram stain of urine showed 
small pleiomorphic Gram-positive rods, and the culture again 
grew an organism that appeared to be Gardnerella, so he was 
started on oral metronidazole and azithromycin. Ultrasound 
of the scrotum showed a mass-like enlargement of the left epi-
didymis tail with cystic changes and calcifications compatible 
with chronic epididymitis with abscess formation (Figure 1A).
At this time, an anaerobic urine culture was ordered because 
Gardnerella is reported to grow better anaerobically, and 
indeed the growth anaerobically was faster and more abun-
dant. However, the VITEK 2 anaerobic card identified the 
organism as Actinobaculum schaalii (renamed Actinotignum 
schaalii), and MALDI-TOF analysis (Bruker, Billerica, MA) 
confirmed it as A.  schaalii. Although there are no Clinical 
and Laboratory Standards Institute standards for interpreting 
results, disk sensitivity testing showed apparent sensitivity to 
penicillin and tetracycline, but resistance to ciprofloxacin and 
erythromycin (although testing was done in a 5% carbon diox-
ide environment, which may have decreased that drug’s activ-
ity). He was switched to doxycycline 100  mg twice daily and 
treated for an additional 4 weeks, to complete a 6-week course. 
He has remained asymptomatic for 6 months after completing 
his treatment, with a normal urinalysis and sterile anaerobic 
urine culture. Follow-up ultrasound examinations were done 
after treatment, and although they were improved and he was 
asymptomatic, the scans remained abnormal until 5  months 
after the end of treatment (Figure 1B).
After the diagnosis was confirmed, paraffin-embedded tissue 
blocks from the most recent prostate biopsy in 2014 were sent 
for 16s DNA analysis but were negative for bacterial DNA.
DISCUSSION
A.  schaalii is considered a commensal bacterium of the genitou-
rinary tract, but is now recognized to be a cause of symptomatic 
UTIs and occasionally associated bacteremia [3, 4]. Recently the full 
genome of this bacterium was sequenced and showed genes encod-
ing attachment pili, which could allow for urothelial colonization 
[8]. Studies on the prevalence of Actinotignum found that the bac-
terium was present in the urine of healthy patients, suggesting it is 
part of the urinary flora. Additional studies using polymerase chain 
reaction analysis identified Actinotignum on skin in the groin region 
of men and in vaginal swabs, but not in fecal samples, indicating it is 
unlikely to be a bowel flora but rather a part of the urogenital flora 
[7]. However, most of the samples tested in these studies came from 
patients with urological disorders, and none excluded chronic pros-
tatitis as the source of A. schaalii. We believe that this case illustrates 
that this organism can cause chronic prostatitis, and that under 
some circumstances it can also be a cause of epididymitis. In this 
case, we hypothesize that the individual had reflux of infected urine 
down his vas deferens into his epididymis [9] when he did a Valsalva 
maneuver while lifting a heavy object.
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Figure 1. (A) Initial ultrasound image demonstrates enlarged and heterogeneous epididymal tail consistent with epididymitis (arrows). Several hypoechoic areas are also 
present (asterisks), consistent with abscesses. Doppler image showed increased vascularity of the left epididymal tail (not shown). Abbreviation: T, testis. (B) Follow-up ultra-
sound 6 months later demonstrates resolution of previous findings with a normal-appearing epididymal tail (arrowheads).
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It is unlikely that A. schaalii is truly an emerging pathogen; 
more likely, we are better at growing and identifying it. It is very 
likely that the incidence of this infection is underestimated, as 
incubation of urine cultures in a 5% CO2 atmosphere is not rec-
ommended [10]. Even if urines are cultured in the permissive 
atmosphere, this organism is unlikely to grow in 48 hours, the 
usual time allotted for incubating urine cultures in the United 
States. Thus, this organism may be another cause of “sterile” 
pyuria or, as in this case, of sterile epididymo-orchitis. Patients 
with recurrent sterile pyuria, particularly elderly patients, or 
those with a predisposing urogenital condition (including 
benign prostatic hyperplasia, catheterization, neurologic blad-
der, and atypical genitourinary anatomy predisposing to reflux) 
should have a urine sample sent for Gram stain and anaerobic 
culture if routine cultures are sterile and the laboratory does not 
incubate urine cultures in a 5% CO2 atmosphere. MALDI-TOF 
is a reliable technology to identify A. schaalii [11]. The VITEK 
2 anaerobic card also identified this isolate, but more studies 
are needed to determine its accuracy, and it is not standard to 
use an anaerobic card to identify a nonanaerobic organism. 
Making the correct identification is important because the 
organism is resistant to co-trimoxasole and fluoroquinolones, 
2 drugs that are commonly given as empiric therapy for urinary 
tract infections. Typically, 2 weeks of treatment with β-lactams 
seems to be effective unless the patient has chronic prostatitis; 
then 4–6 weeks of treatment with an antibiotic that crosses the 
blood-prostate barrier is recommended [12].
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